ProCE Banner Activity

Injectable Long-Acting CAB + RPV: Choices for Mode of Use

Clinical Thought
In this commentary, I share the factors I consider when deciding whether or not to recommend use of the optional 4-week oral lead-in before initiating long-acting cabotegravir plus rilpivirine injections and my thoughts on every-month vs every-2-month dosing.

Released: August 12, 2022

Expiration: August 11, 2023

Share

Faculty

Darrell H S Tan

Darrell H S Tan, MD, FRCPC, PhD

Clinician-Scientist
Division of Infectious Diseases
St Michael's Hospital
Toronto, Ontario, Canada

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Faculty Disclosure

Primary Author

Darrell H S Tan, MD, FRCPC, PhD

Clinician-Scientist
Division of Infectious Diseases
St Michael's Hospital
Toronto, Ontario, Canada

Darrell H. S. Tan, MD, FRCPC, PhD: researcher: AbbVie, Gilead Sciences, GlaxoSmithKline.